Payment overview · 2025
General Payments
$750.83
44 reported records · 14 companies
Healthcare provider profile · identity verified
Laura Thompson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, OH · NPI 1720188899
Verified facts
What the public records show
CMS Open Payments records show Laura Thompson, M.D. received $750.83 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $204.63 | 27.2% | 16 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $123.32 | 16.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $105.32 | 14.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $81.28 | 10.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.68 | 8.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.00 | 4.9% | 2 | 2025 |
| bioMerieux Inc | Unresolved — no canonical attribution shown | $23.64 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.41 | 2.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.73 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.26 | 2.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.53 | 1.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.38 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.08 | 1.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.57 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $750.83 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $123.32 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $102.36 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $98.28 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.28 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $63.11 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $54.64 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.61 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.24 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 29 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 432 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 346 | 106 |
| Losartan Potassium | Losartan Potassium | 308 | 76 |
| Omeprazole | Omeprazole | 242 | 69 |
| Sertraline Hcl | Sertraline Hcl | 239 | 60 |
| Lisinopril | Lisinopril | 222 | 60 |
| Simvastatin | Simvastatin | 182 | 48 |
| Gabapentin | Gabapentin | 166 | 37 |
| Metformin Hcl | Metformin Hcl | 163 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 39 |
| Trazodone Hcl | Trazodone Hcl | 145 | 35 |
| Valsartan | Valsartan | 144 | 37 |
| Glipizide | Glipizide | 134 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 33 |
| Synthroid | Levothyroxine Sodium | 118 | 29 |
| Tramadol Hcl | Tramadol Hcl | 112 | 24 |
| Furosemide | Furosemide | 106 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 31 |
| Prednisone | Prednisone | 98 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 19 |
| Allopurinol | Allopurinol | 93 | 24 |
| Lorazepam | Lorazepam | 93 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 74 | 24 |
| Carvedilol | Carvedilol | 71 | 20 |
| Memantine Hcl | Memantine Hcl | 65 | 17 |
| Montelukast Sodium | Montelukast Sodium | 64 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 23 |
| Eliquis | Apixaban | 59 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 18 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 58 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 15 |
| Chlorthalidone | Chlorthalidone | 57 | 17 |
| Jardiance | Empagliflozin | 57 | 16 |
| Januvia | Sitagliptin Phosphate | 55 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 18 |
| Atenolol | Atenolol | 51 | 14 |
| Celecoxib | Celecoxib | 50 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 21 |
| Potassium Chloride | Potassium Chloride | 49 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 13 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Meloxicam | Meloxicam | 44 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 38 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 34 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 12 |
| Estradiol | Estradiol | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 21 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 14 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 14 |
| Azithromycin | Azithromycin | 21 | 20 |
| Baclofen | Baclofen | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Etodolac | Etodolac | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Lasix | Furosemide | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $750.83 · 44 records | ABBVIE INC. | CREON, EVENITY, FARXIGA, JARDIANCE, LINZESS, MOUNJARO, NEXLETOL, QULIPTA, REPATHA, REXULTI, Sunosi, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZENPEP, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error